Gary Rosner

Professor

1984 …2018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 2 Similar Profiles
Neoplasms Medicine & Life Sciences
Leukemia Medicine & Life Sciences
irinotecan Medicine & Life Sciences
Pharmacokinetics Medicine & Life Sciences
Cyclophosphamide Medicine & Life Sciences
Bone Marrow Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Bone Marrow Transplantation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1984 2018

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial

Santa-Maria, C. A., Bardia, A., Blackford, A. L., Snyder, C., Connolly, R. M., Fetting, J. H., Hayes, D. F., Jeter, S. C., Miller, R. S., Nguyen, A., Quinlan, K., Rosner, G. L., Slater, S., Storniolo, A. M., Wolff, A. C., Zorzi, J., Henry, N. L. & Stearns, V., May 11 2018, (Accepted/In press) In : Breast Cancer Research and Treatment. p. 1-9 9 p.

Research output: Contribution to journalArticle

zoledronic acid
letrozole
Aromatase Inhibitors
exemestane
Pharmacogenetics
Metformin
Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Drug Therapy

Bayesian approaches to evaluating doses of drugs

Rosner, G. L., Apr 1 2018, In : Clinical Advances in Hematology and Oncology. 16, 4, p. 258-261 4 p.

Research output: Contribution to journalComment/debate

Bayes Theorem
Pharmaceutical Preparations

Dependent generalized Dirichlet process priors for the analysis of acute lymphoblastic leukemia

Barcella, W., De Iorio, M., Favaro, S. & Rosner, G. L., Jul 1 2018, In : Biostatistics. 19, 3, p. 342-358 17 p.

Research output: Contribution to journalArticle

Dirichlet Process Prior
Leukemia
Acute
MCMC Algorithm
Bayesian Nonparametrics

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

Zeidner, J. F., Foster, M. C., Blackford, A. L., Litzow, M. R., Morris, L. E., Strickland, S. A., Lancet, J. E., Bose, P., Levy, M. Y., Tibes, R., Gojo, I., Gocke, C. D., Rosner, G. L., Little, R. F., Wright, J. J., Doyle, L. A., Smith, B. D. & Karp, J. E., Sep 1 2018, In : Leukemia Research. 72, p. 92-95 4 p.

Research output: Contribution to journalLetter

alvocidib
Mitoxantrone
Daunorubicin
Cytarabine
Acute Myeloid Leukemia